Labcorp scheduled to speak at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 19, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at KeyBanc Capital Markets'   Life Sciences and MedTech Investor Forum on Wednesday, March 24 at 2:00 p.m. ET.

PathAI and Labcorp broaden strategic collaboration to accelerate use of AI-powered pathology

BOSTON and BURLINGTON, N.C. – March 8, 2021 – PathAI, a global provider of artificial intelligence-powered (AI-powered) technology for use in pathology research, and Labcorp (NYSE: LH), a leading global life sciences company, today announced the broadening of their strategic partnership in the field of AI-powered pathology. The collaboration builds on Labcorp’s past investment in PathAI and the companies’ collaboration on a series of projects, including the deployment of PathAI algorithms in clinical trials managed by Labcorp Drug Development.

Labcorp named to Fast Company’s list of the World’s Most Innovative Companies for 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 9, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been named to Fast Company magazine’s list of 2021 Most Innovative Companies. Since 2008, the annual list has been the definitive source for recognizing the organizations that are transforming industries and shaping society.

Presage sets the stage for commercial expansion with $13M financing and new Phase 0 trial agreements with Merck and Maverick Therapeutics

Seattle, WA – March 2, 2021 – Presage Biosciences, a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology (CIVO®) intratumoral microdosing platform, today announced a $13 million financing and new research collaborations with Merck (NYSE:MRK) and Maverick Therapeutics.

TrakCel fuels growth and increased market access through strategic investment round

Cardiff, UK, March 3, 2021 ‒ TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH). These strategic investments enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion.